Your session is about to expire
← Back to Search
RYZ101 + Standard Treatments for Small Cell Lung Cancer
Study Summary
This trial will test a new drug to see if it can help treat a type of lung cancer when combined with existing treatments.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have not received a live vaccine in the last 4 weeks.I am unable or unwilling to follow the study's requirements.I am eligible for standard cancer treatment including Carboplatin, Etoposide, and Atezolizumab.I have an autoimmune disease or symptoms suggesting one.I cannot take carboplatin or etoposide due to health reasons.My liver tests are within normal limits.I have not had any cancer except for skin cancer or certain treated cancers in the last 3 years.I have brain metastases from cancer and am still experiencing side effects from radiotherapy.I am a man who will use a condom and avoid fathering a child for 3 months after the last study drug dose.I have had immune therapy before, but not cancer vaccines or one cycle of standard treatment during screening.Your calcium levels are too low.My small cell lung cancer is confirmed and I've had at most one treatment with specific drugs.I have had a previous transplant of stem cells or an organ.You are allergic to Chinese hamster ovary cell products or any part of the atezolizumab treatment.I do not have active infections like TB, hepatitis B or C, or HIV, nor am I on antiviral therapy for HBV.I have not had major surgery in the last 4 weeks.I do not have serious heart disease or a long QT interval.My high blood pressure doesn't improve with medication.I have a history of lung scarring or inflammation not caused by infections.I am fully active or restricted in physically strenuous activity but can do light work.I haven't taken any strong antibiotics in the last 2 weeks.You have had serious allergic reactions to similar types of medications in the past.My scans show a positive result for a specific cancer marker and at least half of my cancer spots can be measured.I have not had a severe infection in the last 4 weeks.My blood counts meet the required levels for treatment.You are expected to live for at least 12 weeks.I have undergone peptide receptor radionuclide therapy.I am allergic to certain medical imaging agents or their components.My kidneys work well, with a creatinine clearance rate of 60 mL/min or higher.I have had or will have chest radiation before systemic therapy or had significant radiation to my bone marrow.I haven't taken immunosuppressive drugs in the last 14 days.
- Group 1: RYZ101 + SoC
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is enrollment in this clinical experiment still available?
"Indeed, the clinical trial is actively seeking participants. It was initially made public on October 10th 2022 and has been updated to include new information as of November 18th 2022."
How hazardous are the effects of RYZ101 when administered in conjunction with standard-of-care?
"RYZ101 + SoC's safety was deemed a 1 on the scale of 1 to 3, as this is an early-stage Phase 1 trial with scant evidence supporting its efficacy and safety."
How many participants are being monitored for this clinical experiment?
"Accurate. Clinicaltrials.gov's records suggest that this medical trial is currently recruiting volunteers; the trial was first released on October 10th 2022 and recently updated on November 18th 2022. The study requires 31 participants from one site."
Share this study with friends
Copy Link
Messenger